A61K31/065

Intraocular delivery of bioactive molecules using iontophoresis

Iontophoresis, a minimally-invasive methodology that uses a weak electric current to enhance penetration of ionized molecules into tissues, was found to be an effective technique for the intraocular delivery of large bioactive molecules, specifically lutein.

Intraocular delivery of bioactive molecules using iontophoresis

Iontophoresis, a minimally-invasive methodology that uses a weak electric current to enhance penetration of ionized molecules into tissues, was found to be an effective technique for the intraocular delivery of large bioactive molecules, specifically lutein.

WATER SOLUBLE COMPOSITIONS COMPRISING PURIFIED CANNABINOIDS
20190183853 · 2019-06-20 · ·

This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.

WATER SOLUBLE COMPOSITIONS COMPRISING PURIFIED CANNABINOIDS
20190183853 · 2019-06-20 · ·

This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.

COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS

Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.

COMPOSITIONS AND METHODS OF POTENTIATING ANTIMICROBIALS

Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.

USES OF A CAROTENOID IN THE TREATMENT OR PREVENTION OF STRESS INDUCED CONDITIONS

The invention relates to a carotenoid for use in the treatment or prevention of stress induced conditions, and in particular it relates to the treatment or prevention of a disease mediated by glucocorticoid receptor activity. The invention also relates to a cosmetic method for preventing premature-aging of skin in a subject which comprises administering a carotenoid to said subject. Finally, the invention relates to a method for modulating the activity of a glucocorticoid receptor comprising contacting the receptor with a carotenoid.

METHOD FOR TREATMENT OF VISUAL STRESS CONDITIONS AND COMPOSITIONS USED THEREIN
20190125694 · 2019-05-02 ·

The methods relate to preventing photoreceptor damage caused by blue light by oral administration of a macular carotenoid composition comprising of lutein and zeaxanthin isomers. The photoreceptor damage is prevented through the upregulation of genes and protein synthesis manifested by an increase in the levels gene expression and proteins synthesis of Gnat1, Rhodopsin, NCAM, Rod arrestin, GAP-43, Nrf2, Ho-1 and decrease in the GFAP, NFkB (oxidative stress markers) in rat eye models exposed to visible blue light for various time periods and simultaneously treated with macular carotenoid compositions comprising of lutein zeaxanthin and their isomers. Methods described herein also relate to treatment of visual stress conditions by administering macular carotenoid compositions for treatment headache, blurred vision, photoreceptor degeneration, oxidative stress, endoplasmic reticulum stress and the like, which are caused due to prolonged exposure to blue light source. The methods described herein help to treat visual stress disorders by reducing headache and headache frequency, slowing down photoreceptor degeneration, improvement in oxidative stress and protection of retinal cells from light damage. The compositions herein are safe for humans and other animals for consumption and can be used for treatment of visual stress disorders in the subject in need thereof.

METHOD FOR TREATMENT OF VISUAL STRESS CONDITIONS AND COMPOSITIONS USED THEREIN
20190125694 · 2019-05-02 ·

The methods relate to preventing photoreceptor damage caused by blue light by oral administration of a macular carotenoid composition comprising of lutein and zeaxanthin isomers. The photoreceptor damage is prevented through the upregulation of genes and protein synthesis manifested by an increase in the levels gene expression and proteins synthesis of Gnat1, Rhodopsin, NCAM, Rod arrestin, GAP-43, Nrf2, Ho-1 and decrease in the GFAP, NFkB (oxidative stress markers) in rat eye models exposed to visible blue light for various time periods and simultaneously treated with macular carotenoid compositions comprising of lutein zeaxanthin and their isomers. Methods described herein also relate to treatment of visual stress conditions by administering macular carotenoid compositions for treatment headache, blurred vision, photoreceptor degeneration, oxidative stress, endoplasmic reticulum stress and the like, which are caused due to prolonged exposure to blue light source. The methods described herein help to treat visual stress disorders by reducing headache and headache frequency, slowing down photoreceptor degeneration, improvement in oxidative stress and protection of retinal cells from light damage. The compositions herein are safe for humans and other animals for consumption and can be used for treatment of visual stress disorders in the subject in need thereof.

COMBINATION OF 25-HYDROXYVITAMIN D AND ANTIOXIDANTS/ANTI-INFLAMMATORIES FOR HUMAN NUTRACEUTICALS

This invention relates to the use of the combination of 25-hydroxyvitamin D3 (25-OH D3) and antioxidants/anti-inflammatories (ascorbic acid, vitamin E and at least one carotenoid) to make a pharmaceutical, nutraceutical or food supplement which can ameliorate various problems observed in humans connected with polycystic ovarian 5 syndrome and cardiovascular diseases. Pharmaceuticals, nutraceuticals and food supplements containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.